Investors

News Releases

Keyword Search

Date	Title	Print
05/15/13	Sucampo to be Added to the NASDAQ Biotechnology Index
05/13/13	Sucampo Pharmaceuticals to Host Update on AMITIZA® OIC Indication May 20th
05/07/13	Sucampo Pharmaceuticals, Inc. Reports First Quarter 2013 Financial and Operating Results
04/30/13	Sucampo Pharmaceuticals Announces First Quarter 2013 Results and Operating Highlights Teleconference and Webcast
04/23/13	FDA Approves Supplemental New Drug Application for AMITIZA® (lubiprostone), the First Oral Treatment for Opioid-induced Constipation in Adults with Chronic Non-Cancer Pain
03/29/13	Sucampo Pharmaceuticals to Present at 20th Annual Future Leaders in the Biotech Industry Conference
03/13/13	Sucampo Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
03/06/13	Sucampo Pharmaceuticals Announces Fourth Quarter and Full Year 2012 Financial Results and Operating Highlights Teleconference and Webcast
03/04/13	Sucampo and Festival Partnership Continues to Blossom
03/01/13	Sucampo Appoints Barbara A. Munder and Maureen E. O’Connell to Board of Directors
02/19/13	Sucampo Announces Commercial Availability of RESCULA in U.S. Pharmacies
02/08/13	Sucampo Files Patent Infringement Lawsuit Against Anchen Pharmaceuticals and Par Pharmaceuticals
02/06/13	Sucampo Pharmaceuticals to Present at Investment Conferences
02/04/13	Sucampo Announces Japanese Government Funding for Unoprostone Isopropyl Development in Retinitis Pigmentosa
01/03/13	Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Biotech Showcase(TM) 2013 Conference